Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans

Hepatology

Volumn 48, Issue 1, 2008, Pages 70-79

  Harris, Rebecca A ^a,b,c   Sugimoto, Kazushi ^a,b   Kaplan, David E ^a,b   Ikeda, Fusao ^a,b   Kamoun, Malek ^a   Chang, Kyong Mi ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HAVERFORD COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CLEARANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

AFRICAN AMERICANS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGENETICS; MIDDLE AGED; VIRAL LOAD;

EID: 47149118872     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22287     Document Type: Article

References (56)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. HEPATOLOGY 1997;26(Suppl):15S-20S.
2. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
3. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
4. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-714.
5. Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, et at. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 2007;132:654-666.
6. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. HEPATOLOGY 2003;37:590-599.
7. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.
8. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000;119:1385-1396.
9. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. HEPATOLOGY 1999;30:787-793.
10. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6:66-70.
11. He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. HEPATOLOGY 2006;44:352-359.
12. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477.
13. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-706.
14. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-874.
15. Rauch A, Laird R, McKinnon E, Telenti A, Furrer H, Weber R, et al. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007;69(Suppl 1):237-240.
16. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004;5:237-245.
17. Oleksyk TK, Thio CL, Truelove AL, Goedert JJ, Donfield SM, Kirk GD, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005;6:347-357.
18. Kimura T, Saito T, Yoshimura M, Yixuan S, Baba M, Ji G, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006;193:1371-1374.
19. Fremont DH, Hendrickson WA, Marrack P, Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science 1996;272:1001-1004.
20. Fleury S, Thibodeau J, Croteau G, Labrecque N, Aronson HE, Cantin C, et al. HLA-DR polymorphism affects the interaction with CD4. J Exp Med 1995;182:733-741.
21. Villadangos JA. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 2001;38:329-346.
22. Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol 2002;38:1039-1049.
23. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113:1675-1681.
24. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus: members of the Trent Hepatitis C Virus Study Group. J Infect Dis 1998;178:39-44.
25. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999;354:2119-2124.
26. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999;30:984-989.
27. Harcourt G, Hellier S, Bunce M, Satsangi J, Collier J, Chapman R, et al. Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepatol 2001;8:174-179.
28. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001;184:16-21.
29. Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998;28:1-7.
30. McKiernan SM, Hagan R, Curry M, McDonald GS, Nolan N, Crowley J, et al. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000;118:1124-1130.
31. Sugimoto K, Kaplan DE, Ikeda F, Ding J, Schwartz J, Nunes FA, et al. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol 2005;79:6976-6983.
32. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex-vivo in persistent HCV infection. HEPATOLOGY 2003;38:1437-1448.
33. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997;100:2376-2385.
34. Keppel G, Suafley W Jr, Tokunuga H. Introduction to Design and Analysis: A Student's Handbook. 2nd ed. New York, NY: W.H. Freeman; 1992.
35. Tang TF, Huang AY, Pappas A, Slack R, Ng J, Hartzman RJ, et al. Relative frequencies of DRB1*11 alleles and their DRB3 associations in five major population groups in a United States bone marrow registry. Hum Immunol 2000;61:820-827.
36. Hristova-Dimceva A, Verduijn W, Schipper RF, Schreuder GM. HLA-DRB and -DQB1 polymorphism in the Macedonian population. Tissue Antigens 2000;55:53-56.
37. Cramp ME, Rossol S, Carucci P, Williams R, Naoumov NV, Donaldson PT. The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell. J Hepatol 1998;28:94.
38. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-5545.
39. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6:873-879.
40. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC. Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 1994;369:652-654.
41. Henderson KN, Tye-Din JA, Reid HH, Chen Z, Borg NA, Beissbarth T, et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 2007;27:23-34.
42. Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-2035.
43. Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr Opin Immunol 2005;17:526-531.
44. Provenzano M, Panelli MC, Mocellin S, Bracci L, Sais G, Stroncek DF, et al. MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol Med 2006;12:465-472.
45. Hong X, Yu RB, Sun NX, Wang B, Xu YC, Wu GL. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005;11:7302-7307.
46. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007;13:1770-1787.
47. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004;36:1312-1318.
48. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. HEPATOLOGY 2004;40:108-114.
49. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. HEPATOLOGY 2000;31:1334-1337.
50. Azocar J, Clavijo OP, Yunis EJ. MHC class II genes in HCV viral clearance of hepatitis C infected Hispanic patients. Hum Immunol 2003;64:99-102.
51. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998;29:207-213.
52. Rosen HR, Weston SJ, Im K, Yang H, Burton JR Jr., Erlich H, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. HEPATOLOGY 2007;46:350-358.
53. Ulsenheimer A, Lucas M, Seth NP, Tilman Gerlach J, Gruener NH, Loughry A, et al. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepatol 2006;13:708-714.
54. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming in memory T-cell development. Curr Opin Immunol 2004;16:217-225.
55. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003;300:339-342.
56. Hershberg RM, Cho DH, Youakim A, Bradley MB, Lee JS, Framson PE, et al. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest 1998;102:792-803.